Dear Fellow Medical Professionals,

Our Hematology disease oriented groups at Mayo Clinic in Rochester have adopted some new approaches to the treatment of well recognized disorders, and we would like to make you aware of them. In addition, we want to let you know about some opportunities for your patients to benefit from some novel therapies.

We hope you find this newsletter valuable in reviewing new applications, treatment algorithms, novel therapies, and clinical trials which we can make available to your patients. At the same time, please be assured that while we appreciate the opportunity to collaborate with you on your patients’ treatment plans, we will always respect your relationships with them.

We send this in the spirit of providing a framework of cooperative treatment options and consultations for your patients.

We welcome feedback about what you find valuable and what you do not. In addition, please feel free to contact the individual members of our disease oriented groups to assist in the care of your patients (see back page).

Mark R. Litzow, MD, leads the Acute Leukemia Group. This group has played a national and international role in the development of clinical trials for the treatment of acute myeloid and acute lymphoblastic leukemia through the auspices of the Eastern Cooperative Oncology Group. Mayo Clinic has protocols active for treatment of patients with myeloproliferative disorders, myelodysplastic syndromes, and acute leukemia.

The Myeloid Disease Group in the Division of Hematology is world renowned for its expertise in the diagnosis and treatment of chronic myeloid disorders and acute leukemia. Under the direction of Ayaiew Terreri, MD, the Chronic Myeloid Group has made seminal observations in the diagnosis, prognosis, and treatment of myeloproliferative disorders. The group played a key role in the discovery of the JAK2 V617F mutation and is at the forefront of the development of therapeutic agents to inhibit JAK2.
Blood and Marrow Transplant Group
The Blood and Marrow Transplant program at Mayo Clinic in Rochester performs in excess of 300 transplants per year, utilizing both autologous and allogeneic. There are active transplant approaches for myeloma, acute and chronic leukemias, amyloidosis, and lymphoma.

CLL Group protocols
Asymptomatic
MC0785, Alemtuzumab, rituximab, and GM-CSF for early stage (Rai 0–2, who do not meet standard criteria for treatment) and who have high risk CLL (17p13-, 11q22-, IGVH unmutated + ZAP-70+ ± CD38+). 6 weeks duration and after initial training, alemtuzumab and GM-CSF can be self administered.

Symptomatic-initial Therapy
MC0783, PCR + bevaxizumab – PCR with concurrent bevaxizumab.


Recurrent
MC088C, Treatment of Relapsed/Refractory CLL/SLL with Everolimus (RAD001) and Alemtuzumab: A Phase I/II Study.
LS0881, Relapsed/refractory CLL/SLL with pentostatin, alemtuzumab, and low dose rituximab. For patients with resistant disease, including 17p13 – duration (8-12 weeks).

Familial CLL
Patients with CLL, who have at least one living parent, sibling or close relative with CLL or NHL. To register call 1-800-610-3291, there's no need to travel to the Mayo Clinic.

For more information: www.mayoclinic.org /chronic-lymphocytic-leukemia/clntrials.html.

Coagulation Group
Venous Thromboembolism (VTE) Research: Family-based VTE Study (DQ00235) A linkage-based approach to identify VTE disease susceptibility genes among families with three or more living members affected with VTE; visit the following web site to participate: www.haatechnology.com/survey/register.html.

The Role of Molecular Analysis in Antithrombin, Protein C or Protein S Deficiency Diagnosis and Management. (HL83797) The aim of this study is to test molecular analysis as predictors of thrombosis and recurrent pregnancy loss phenotype penetrance and severity among family members with deficiency of antithrombin, protein C or protein S.

Warfarin Management
The role of pharmacogenetics in the management of warfarin therapy. An NIH-funded clinical trial randomizing patients requiring warfarin therapy to management with or without information on patient warfarin pharmacogenetics.

Dysproteinemias
For patients with newly diagnosed myeloma who have received 1 or more cycles of therapy off-study and for patients who have completed induction therapy but wish to delay transplant: E1A05 Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade)-Lenalidomide (Revlimid) – Dexamethasone (VRD) versus Bortezomib (Velcade) – Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen.

For patients with relapsed myeloma who have failed standard therapy: MC038C Phase I Trial of Systemic Administration of Edmonton Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma.

For patients with newly diagnosed amyloidosis. Patients can choose which arm they want to enter: MC0482 Phase III Trial of Stem Cell Transplantation Compared to Parenteral Melphalan and Oral Dexamethasone in the Treatment of Primary Systemic Amyloidosis (AL).


Non-Malignancy Hematology
The members of the non-malignant hematology group are available to provide consultation in cases of anemias, thrombocytopenias, leukopenias, hemoglobinopathies, and other hematologic cases or diagnostic dilemmas.

Lymphoma Group
New Untreated Diffuse
Large Cell Lymphoma
MC078E Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide,
Doxorubicin, Vincristine and Prednisone (R2chop) Chemoimmunotherapy in Patients with Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma.

**New Untreated Follicular Lymphoma**

**N0682 A Phase II Clinical Trial of**

Denileukin Diftitox in Combination with Rituiximab in Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma.

**New Untreated Mantle Cell**

**N078D Phase I/II Trial of**

Rituiximab, Cladribine, and Temsirolimus (RCT)

Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL).

**Relapsed Non-Hodgkin or Hodgkin Lymphoma or Waldenstrom’s Macroglobulinemia**

**MC0886 Histone Deacetylase (HDAC)**

Inhibitor LBH589 (Panobinostat) + the mTOR Inhibitor RAD001 (Everolimus).

**MC048G – Single agent RAD001.**

**LS0689 – RAD001 + Sorafenib.**

**Relapsed Mantle Cell**

**CC-5013 – MCL-001 Revlimid.**

**CRAD001N2201 – RAD001.**

For more information:


**Leukemia/Myelodysplasia/ Myeloproliferative Group**

For patients with anemia (Hgb <10 g/dL) or marked splenomegaly a trial of the thalidomide analogue, pomalidomide:

**MC078B A Phase I/II, Prospective, Open-Label Study To Determine the Safety And Efficacy Of CC-4047 in Patients With Primary, Post Polycythemia Vera, or Post Essential Thrombocytethemia Myelofibrosis.**

For patients with MDS of IPSS score Low or INT-1 with symptomatic anemia:

**E2905 Randomized Phase III Trial**

Comparing the Frequency or Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alpha (Procrit) in Subjects with Low – or Intermediate-1 Risk MDS and Symptomatic Anemia.

For patients with AML in first relapse or refractory to induction therapy:

**E1906 A Phase II Randomized Trial of**

Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML)

For more information:

www.mayoclinic.org/myelofibrosis/clintrials.html,

www.mayoclinic.org/myelodysplastic-syndromes/clintrials.html and


**Staff Spotlight**

**Grzegorz S Nowakowski, MD**

Dr Nowakowski joined Mayo Clinic in 2008. He attended medical school in Warsaw, Poland, trained in Internal Medicine at Yale University Medical School, and trained in Hematology/Oncology at Mayo Clinic. Following his fellowship, he spent two years as a Mayo Clinic scholar and then returned as a member of the Mayo Lymphoma Group. His interests are new therapies for lymphoma, chronic lymphocytic leukemia, and multiple myeloma, biology of lymphoproliferative disorders and therapeutic targeting of the interface between the tumor and the microenvironment.

**Carrie Thompson, MD**

Dr Thompson recently joined Mayo Clinic. She attended medical school at Saint Louis University, and trained in Internal Medicine and Hematology/Oncology at Mayo Clinic. Following fellowship, she spent two years in New York City where she obtained a masters degree in Clinical Epidemiology and Health Services Research. She also did clinical research with the lymphoma group at Weill Cornell Medical College. Her research interests include prognostic factors in hematological malignancies and long-term effects of cancer treatment, including cardiac disease and quality of life.

**Francis Buadi, MD**

Dr Buadi joined Mayo Clinic in 2007. He obtained his medical degree at the School of Medical Sciences, University of Science and Technology, Ghana. He completed his internship and internal medicine residency at St. Agnes Hospital in Baltimore, followed by a Hematology/Oncology fellowship at the University of Maryland. After another fellowship in bone marrow transplantation at Mayo and some time on the faculty at the University of Tennessee, he is now back at Mayo as a member of the Myeloma/Amyloidosis/Dysproteinemia Group. His current interests are novel therapies for myeloma and amyloidosis, and stem cell transplantation.
Contact Us
Hematology Referrals and Consultations
507-284-5363

For all other referrals and consultations
800-533-1564

C. Christopher Hook, MD
Robert D. McBane, MD
William L. Nichols, Jr, MD
Animesh D. Pardanani, MD
Rajiv K. Pruthi, MD
Alexandra P. Wolanskyj, MD
Waldermar E. Wysokinski, MD

Francis Buadi, MD
David Dingli, MD
dingli.david@mayo.edu
Angela Dispenzieri, MD
dispenzieri.angela@mayo.edu
Morie A. Gertz, MD
Suzanne R. Hayman, MD
Shaji K. Kumar, MD
Martha Q. Lacy, MD
Lympoma Transplant Group
Stephen M. Ansell, MD, PhD
ansell.stephen@mayo.edu
David J. Inwards, MD
Patrick B. Johnston, MD
Ivana N. Micalef, MD
Luis F. Porrata, MD
Myeloid/Aplastic Anemia
Transplant Group
Dennis A. Gastineau, MD
William J. Hogan, MD (chair)
Mark R. Litzow, MD
litzow.mark@mayo.edu

S. Vincent Rajkumar, MD
(r) chair
rajkumar.vincent@mayo.edu
Stephen J. Russell, MD, PhD
Thomas E. Witzig, MD
Steven R. Zelenrust, MD, PhD
Kristen Detweiler Shott, NP

Lymphoma Group
Stephen M. Ansell, MD, PhD
ansell.stephen@mayo.edu
Joseph P. Coigan, MD
Thomas M. Habermann, MD
Patrick B. Johnston, MD
David J. Inwards, MD
Svetomir N. Markovic, MD, PhD

Ivana N. Micalef, MD
Grzegorz Nowakowski, MD
Luis F. Porrata, MD
Carrie A. Thompson, MD
Thomas E. Witzig, MD (chair)
witzig.thomas@mayo.edu
Robin Klebig, NP

Leukemia/Myelodysplasia/
Myeloproliferative Group
Aneel Ashrani, MD
Michelle A. Elliott, MD
William J. Hogan, MD
C. Christopher Hook, MD
Kebede Hussein, MD
hussein.kebede@mayo.edu
Scott H. Kaufmann, MD
Louis Letendre, MD
Mark R. Litzow, MD (chair)
litzow.mark@mayo.edu
Animesh D. Pardanani, MD
Rajiv K. Pruthi, MD
Ayalew Teferra, MD
Alexandra P. Wolanskyj, MD

Non-Malignancy Group
Timothy G. Call, MD
call.timothy@mayo.edu
Michelle, Elliott, MD
C. Christopher Hook, MD
(r) chair
William J. Hogan, MD
James Hoyer, MD
Kebede Hussein, MD
Louis Letendre, MD
Mark R. Litzow, MD
litzow.mark@mayo.edu
Alexandra P. Wolanskyj, MD

MAYO CLINIC

4500 San Pablo Road
Jacksonville, FL 32224
www.mayoclinic.org

©2009 Mayo Foundation for Medical Education and Research (MFMER).
All rights reserved. MAYO, MAYO CLINIC and the triple-shield Mayo logo are trademarks and service marks of MFMER.